Phase 1/2 Study of Investigational Agents with Pembrolizumab in Advanced Esophageal Cancer
A Phase 1/2 study is underway to evaluate investigational agents with or without pembrolizumab in patients with advanced esophageal squamous cell carcinoma.
Indication
Clinical and regulatory intelligence for Esophageal Cancer with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.